Global Biopharma Solutions Leader Selects Kneat to Drive Digital Validation Excellence

Executive Summary

• Kneat announced a Master Services Agreement with a leading global biopharma research and manufacturing company, covering deployment of Kneat’s digital validation platform at multiple manufacturing sites worldwide.
• The partnership is positioned as a “strategic win” that should drive measurable ROI for the customer and accelerate Kneat’s revenue growth.
• Management highlighted the deal as evidence of expanding market adoption of Kneat’s platform across the pharmaceutical supply chain.

Key Details

• Agreement Scope: Master Services Agreement to implement Kneat Gx digital validation platform for equipment validation at several manufacturing sites of the biopharma partner.
• Customer Profile: A European‑headquartered organization with >13,000 employees and operations in more than 60 locations worldwide; a leading provider of biopharma research and manufacturing technologies.
• Expected Benefits: Harmonization and standardization of validation processes, operational excellence, long‑term value creation, and measurable ROI for the customer.
• Revenue Impact: Management expects the partnership to contribute to strong revenue growth and anticipates expanded enterprise‑wide use over time.
• CEO Quote: “Welcoming one of the world’s foremost biopharma processing solution providers is an exciting start to 2026… This partnership underscores Kneat’s growing role across the broader pharmaceutical manufacturing supply chain.” – Eddie Ryan, CEO, Kneat

Notable Quotes

• “Our shared mission is to help life sciences companies deliver therapies to patients to the highest standards of safety and quality.” – Eddie Ryan, Chief Executive Officer
• “By leveraging Kneat’s platform, the Company will harmonize and standardize validation processes across its global operations, driving operational excellence and long‑term value.” – Company statement